147 related articles for article (PubMed ID: 29913272)
1. siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
Valencia-Serna J; Aliabadi HM; Manfrin A; Mohseni M; Jiang X; Uludag H
Eur J Pharm Biopharm; 2018 Sep; 130():66-70. PubMed ID: 29913272
[TBL] [Abstract][Full Text] [Related]
2. siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers.
Valencia-Serna J; Kucharski C; Chen M; Kc R; Jiang X; Brandwein J; Uludağ H
J Control Release; 2019 Sep; 310():141-154. PubMed ID: 31430499
[TBL] [Abstract][Full Text] [Related]
3. Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation.
Valencia-Serna J; Gul-Uludağ H; Mahdipoor P; Jiang X; Uludağ H
J Control Release; 2013 Dec; 172(2):495-503. PubMed ID: 23726887
[TBL] [Abstract][Full Text] [Related]
4.
Kc R; Thapa B; Ubeda A; Jiang X; Uludağ H
Stem Cells Dev; 2019 Jun; 28(11):734-744. PubMed ID: 30585758
[TBL] [Abstract][Full Text] [Related]
5. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
Jyotsana N; Sharma A; Chaturvedi A; Budida R; Scherr M; Kuchenbauer F; Lindner R; Noyan F; Sühs KW; Stangel M; Grote-Koska D; Brand K; Vornlocher HP; Eder M; Thol F; Ganser A; Humphries RK; Ramsay E; Cullis P; Heuser M
Ann Hematol; 2019 Aug; 98(8):1905-1918. PubMed ID: 31104089
[TBL] [Abstract][Full Text] [Related]
6. Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells.
Arthanari Y; Pluen A; Rajendran R; Aojula H; Demonacos C
J Control Release; 2010 Aug; 145(3):272-80. PubMed ID: 20403398
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol grafted cationic lipopolymers: Potential siRNA carriers for selective chronic myeloid leukemia therapy.
Remant KC; Thapa B; Valencia-Serna J; Domun SS; Dimitroff C; Jiang X; Uludağ H
J Biomed Mater Res A; 2020 Mar; 108(3):565-580. PubMed ID: 31714657
[TBL] [Abstract][Full Text] [Related]
8. Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models.
Ansari AS; K C R; Morales LC; Nasrullah M; Meenakshi Sundaram DN; Kucharski C; Jiang X; Brandwein J; Uludağ H
J Control Release; 2024 Mar; 367():821-836. PubMed ID: 38360178
[TBL] [Abstract][Full Text] [Related]
9. siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model.
Freire JM; Rego de Figueiredo I; Valle J; Veiga AS; Andreu D; Enguita FJ; Castanho MA
J Control Release; 2017 Jan; 245():127-136. PubMed ID: 27890856
[TBL] [Abstract][Full Text] [Related]
10. Biodegradable charged polyester-based vectors (BCPVs) as an efficient non-viral transfection nanoagent for gene knockdown of the BCR-ABL hybrid oncogene in a human chronic myeloid leukemia cell line.
Yang C; Panwar N; Wang Y; Zhang B; Liu M; Toh H; Yoon HS; Tjin SC; Chong PH; Law WC; Chen CK; Yong KT
Nanoscale; 2016 Apr; 8(17):9405-16. PubMed ID: 27092903
[TBL] [Abstract][Full Text] [Related]
11. Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
Koldehoff M; Zakrzewski JL; Beelen DW; Elmaagacli AH
Cancer Gene Ther; 2013 Jul; 20(7):421-7. PubMed ID: 23788109
[TBL] [Abstract][Full Text] [Related]
12. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
[TBL] [Abstract][Full Text] [Related]
13. The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.
Ru Y; Wang Q; Liu X; Zhang M; Zhong D; Ye M; Li Y; Han H; Yao L; Li X
Sci Rep; 2016 Jun; 6():28352. PubMed ID: 27329306
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
Sengupta A; Banerjee D; Chandra S; Banerjee S
J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
[TBL] [Abstract][Full Text] [Related]
15. Cell-penetrating peptide and cationic liposomes mediated siRNA delivery to arrest growth of chronic myeloid leukemia cells in vitro.
Vysochinskaya V; Zabrodskaya Y; Dovbysh O; Emelyanov A; Klimenko V; Knyazev N; Terterov I; Egorova M; Bogdanov A; Maslov M; Vasin A; Dubina M
Biochimie; 2024 Jun; 221():1-12. PubMed ID: 38215931
[TBL] [Abstract][Full Text] [Related]
16. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
[TBL] [Abstract][Full Text] [Related]
17. Targeting bcr-abl transcripts with siRNAs in an imatinib-resistant chronic myeloid leukemia patient: challenges and future directions.
Koldehoff M
Methods Mol Biol; 2015; 1218():277-92. PubMed ID: 25319658
[TBL] [Abstract][Full Text] [Related]
18. Bcr-abl silencing by specific small-interference RNA expression vector as a potential treatment for chronic myeloid leukemia.
Zaree Mahmodabady A; Javadi HR; Kamali M; Najafi A; Hojati Z
Iran Biomed J; 2010; 14(1-2):1-8. PubMed ID: 20683492
[TBL] [Abstract][Full Text] [Related]
19. Efficient disruption of bcr-abl gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cells.
Luo Z; Gao M; Huang N; Wang X; Yang Z; Yang H; Huang Z; Feng W
J Exp Clin Cancer Res; 2019 May; 38(1):224. PubMed ID: 31138265
[TBL] [Abstract][Full Text] [Related]
20. Systemic delivery of CRISPR/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy.
Liu Y; Zhao G; Xu CF; Luo YL; Lu ZD; Wang J
Biomater Sci; 2018 May; 6(6):1592-1603. PubMed ID: 29725684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]